Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239394 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01239394: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01239394 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01239394, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells. It is approved by the FDA for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence of success in people who's B-cell lymphomas have relapsed after initial treatments. In this research study we are looking to see if ofatumumab is effective and safe in treating previously untreated B-cell NHL.
Interventions
- DRUG ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01239394
The ClinicalTrials.gov registry entry for NCT01239394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ofatumumab is the first listed.
NCT01239394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01239394 about?
NCT01239394 is a clinical study titled "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma". Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells. It is approved by the FDA for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence of success in people who's ...
What is the current status of trial NCT01239394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-12. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01239394?
The interventions under investigation include: ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01239394?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.